Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea.
|ClinicalTrials.gov Identifier: NCT00812188|
Recruitment Status : Completed
First Posted : December 22, 2008
Last Update Posted : December 9, 2014
|Condition or disease||Intervention/treatment|
|Symmetric Limited Morphea.||Other: Medium Dose UVA-1 Other: High Dose UVA-1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||24 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Prospective, Open Label Trial of High Dose UVA-1, 3x/Week or Medium Dose UVA-1, 3x/Week vs. Fluocinonide 0.05% Cream Treatment of Morphea|
|Study Start Date :||November 2004|
|Primary Completion Date :||November 2009|
|Study Completion Date :||November 2009|
Active Comparator: Medium Dose UVA-1
Medium dose (60 J/cm2) UVA-1 3x/week for 12 weeks to one morphea plaque and fluocinonide 0.05% cream to another morphea plaque twice daily for twelve weeks.
Other: Medium Dose UVA-1
UVA-1 phototherapy treatment (60 J/cm2) three times per week for 12 weeks.
Active Comparator: High Dose UVA-1
High dose UVA-1 treatment 3x/week for 12 weeks to one morphea plaque and fluocinonide 0.05% cream twice daily for 12 weeks to another morphea plaque.
Other: High Dose UVA-1
High dose (120 J/cm2)UVA-1 phototherapy three times per week for 12 weeks.
- Efficacy of UVA-1 treatment vs. topical steroid. [ Time Frame: 5 years ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00812188
|United States, Texas|
|UT Southwestern Medical Center at Dallas - Department of Dermatology Clinical Trials|
|Dallas, Texas, United States, 75390|
|Principal Investigator:||Heidi Jacobe, M.D.||UT Southwestern Medical Center at Dallas|